ProMIS Neurosciences (PMN) Net Income towards Common Stockholders (2021 - 2026)

ProMIS Neurosciences (PMN) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$8.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 12.2% year-over-year to -$8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.6 million (down 4248.84% YoY) and the FY2025 annual result came in at -$39.7 million, down 1529.33% from the prior year.
• Net Income towards Common Stockholders improved to -$8.2 million in Q1 2026, from -$10.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $28.9 million in Q4 2022 to a low of -$11.6 million in Q3 2025.
• A 5-year average of -$2.4 million and a median of -$3.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 1247.26% — and 2025, when it sank 4381.01%.
• Tracing PMN's Net Income towards Common Stockholders over 5 years: stood at $28.9 million in 2022, then plunged by 112.41% to -$3.6 million in 2023, then jumped by 93.35% to -$238207.0 in 2024, then slumped by 4381.01% to -$10.7 million in 2025, then increased by 22.76% to -$8.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$8.2 million (Q1 2026), -$10.7 million (Q4 2025), and -$11.6 million (Q3 2025), per Business Quant data.